FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019988249> ?p ?o ?g. }

• W2019988249 endingPage "138" @default.
• W2019988249 startingPage "131" @default.
• W2019988249 abstract "This retrospective study aimed at determining the prognostic significance of neuroendocrine markers chromogranin A (CgA), pro-gastrin releasing peptide (ProGRP) and neuron-specific enolase (NSE), together with the cytokeratin 19 marker CYFRA 21-1 in small cell lung cancer (SCLC). A total of 148 histologically proven and previously untreated SCLC patients were included. Among them 118 patients received a cisplatin–etoposide combination or cisplatin–etoposide–cyclophosphamide-4′-epidoxorubicin combination. All tumour markers were tested using immunoradiometric assays except for ProGRP which was tested using an enzyme-linked immunosorbent assay. The thresholds for marker serum titrations were 53 pg/ml, 65, 17, and 3.6 ng/ml for ProGRP, CgA, NSE and CYFRA 21-1 respectively. Univariate analysis showed that patients affected by one of the following characteristics proved to have a significant shorter survival in comparison with the opposite status of each variable: age over 63 years, extensive-stage, serum LDH level higher than 600 U/l, serum NSE level higher than 17 ng/ml, serum CgA level higher than 65 ng/ml and serum CYFRA 21-1 level higher than 3.6 ng/ml. In addition, there was a trend towards a statistical significance for a high serum alkaline phosphatase level and a performance status equal to or worse than two. The following variables were independent determinants of a poor outcome: a poor performance status (hazard ratio [95% confidence interval]: 1.51 [1.02–2.22]), a high CgA level (HR: 1.61 [1.06–2.45]), a high CYFRA 21-1 level (HR: 2.10 [1.40–3.14]) and an age older than 63 years (HR: 1.68 [1.14–2.48]). When the multivariate analysis was restricted to patients receiving a cisplatin–etoposide-based chemotherapy, the same variables were prognostic determinants with nearly similar hazard ratios. In conclusion, aside classical variables such as age and performance status, high serum CYFRA 21-1 and high serum CgA level in SCLC are both prognostic determinants of prognosis, in particular in patients receiving conventional chemotherapy consisting of cisplatin and etoposide-based combinations." @default.
• W2019988249 created "2016-06-24" @default.
• W2019988249 creator A5007996044 @default.
• W2019988249 creator A5028969883 @default.
• W2019988249 creator A5035680745 @default.
• W2019988249 creator A5053668514 @default.
• W2019988249 creator A5061348202 @default.
• W2019988249 creator A5063545817 @default.
• W2019988249 date "2003-02-01" @default.
• W2019988249 modified "2023-10-17" @default.
• W2019988249 title "Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer" @default.
• W2019988249 cites W1495781375 @default.
• W2019988249 cites W1505569109 @default.
• W2019988249 cites W1580788756 @default.
• W2019988249 cites W158341068 @default.
• W2019988249 cites W1898563448 @default.
• W2019988249 cites W1900401995 @default.
• W2019988249 cites W1979300931 @default.
• W2019988249 cites W1984492331 @default.
• W2019988249 cites W1996285570 @default.
• W2019988249 cites W1998150326 @default.
• W2019988249 cites W1998172322 @default.
• W2019988249 cites W2010601423 @default.
• W2019988249 cites W2016693266 @default.
• W2019988249 cites W2026317796 @default.
• W2019988249 cites W2038212496 @default.
• W2019988249 cites W2051116975 @default.
• W2019988249 cites W2053904115 @default.
• W2019988249 cites W2055939633 @default.
• W2019988249 cites W2073683299 @default.
• W2019988249 cites W2076578875 @default.
• W2019988249 cites W2084947601 @default.
• W2019988249 cites W2085099468 @default.
• W2019988249 cites W2093188948 @default.
• W2019988249 cites W2137115482 @default.
• W2019988249 cites W2137988656 @default.
• W2019988249 cites W2150004274 @default.
• W2019988249 cites W2157275688 @default.
• W2019988249 cites W2161351539 @default.
• W2019988249 cites W2173643829 @default.
• W2019988249 cites W2340678921 @default.
• W2019988249 cites W2477197647 @default.
• W2019988249 cites W2612134078 @default.
• W2019988249 cites W773474473 @default.
• W2019988249 cites W96751186 @default.
• W2019988249 doi "https://doi.org/10.1016/s0169-5002(02)00513-5" @default.
• W2019988249 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12581564" @default.
• W2019988249 hasPublicationYear "2003" @default.
• W2019988249 type Work @default.
• W2019988249 sameAs 2019988249 @default.
• W2019988249 citedByCount "88" @default.
• W2019988249 countsByYear W20199882492012 @default.
• W2019988249 countsByYear W20199882492013 @default.
• W2019988249 countsByYear W20199882492014 @default.
• W2019988249 countsByYear W20199882492015 @default.
• W2019988249 countsByYear W20199882492016 @default.
• W2019988249 countsByYear W20199882492017 @default.
• W2019988249 countsByYear W20199882492018 @default.
• W2019988249 countsByYear W20199882492019 @default.
• W2019988249 countsByYear W20199882492020 @default.
• W2019988249 countsByYear W20199882492021 @default.
• W2019988249 countsByYear W20199882492022 @default.
• W2019988249 countsByYear W20199882492023 @default.
• W2019988249 crossrefType "journal-article" @default.
• W2019988249 hasAuthorship W2019988249A5007996044 @default.
• W2019988249 hasAuthorship W2019988249A5028969883 @default.
• W2019988249 hasAuthorship W2019988249A5035680745 @default.
• W2019988249 hasAuthorship W2019988249A5053668514 @default.
• W2019988249 hasAuthorship W2019988249A5061348202 @default.
• W2019988249 hasAuthorship W2019988249A5063545817 @default.
• W2019988249 hasConcept C126322002 @default.
• W2019988249 hasConcept C142724271 @default.
• W2019988249 hasConcept C143998085 @default.
• W2019988249 hasConcept C144301174 @default.
• W2019988249 hasConcept C176685330 @default.
• W2019988249 hasConcept C188618488 @default.
• W2019988249 hasConcept C204232928 @default.
• W2019988249 hasConcept C207103383 @default.
• W2019988249 hasConcept C2776256026 @default.
• W2019988249 hasConcept C2776694085 @default.
• W2019988249 hasConcept C2778119113 @default.
• W2019988249 hasConcept C2778758028 @default.
• W2019988249 hasConcept C2779012181 @default.
• W2019988249 hasConcept C38180746 @default.
• W2019988249 hasConcept C44249647 @default.
• W2019988249 hasConcept C71924100 @default.
• W2019988249 hasConcept C77231918 @default.
• W2019988249 hasConcept C90924648 @default.
• W2019988249 hasConceptScore W2019988249C126322002 @default.
• W2019988249 hasConceptScore W2019988249C142724271 @default.
• W2019988249 hasConceptScore W2019988249C143998085 @default.
• W2019988249 hasConceptScore W2019988249C144301174 @default.
• W2019988249 hasConceptScore W2019988249C176685330 @default.
• W2019988249 hasConceptScore W2019988249C188618488 @default.
• W2019988249 hasConceptScore W2019988249C204232928 @default.
• W2019988249 hasConceptScore W2019988249C207103383 @default.
• W2019988249 hasConceptScore W2019988249C2776256026 @default.
• W2019988249 hasConceptScore W2019988249C2776694085 @default.

• next